One major advantage of pursing that line of inquiry is the fact that for several clinical grade inhibitors, such as EZH2 and embryonic ectoderm development (EED) proteins, data on human pharmacokinetics, pharmacodynamics, and toxicity and, in some cases, clinical trial outcomes in other cancer types are already available [77]. This evidence concerns the gene EED and cancer.